Date: 2015-07-22
Type of information: Series B financing round
Company: KalVista Pharmaceuticals (UK)
Investors: Novo A/S (Denmark) RA Capital Management (USA - MA) SV Life Sciences (UK - USA) Longwood Fund (USA) Venrock (USA - CA)
Amount: $33 million
Funding type: series B financing round
Planned used: KalVista Pharmaceuticals has developed and patented a diverse pipeline of highly selective and potent plasma kallikrein inhibitors designed for different routes of administration. These funds will enable the Company to accelerate the advancement of these drug candidates through to clinical testing for multiple disease indications. The most advanced program, an intravitreally administered plasma kallikrein inhibitor has just completed its first-in-human study and will move into Phase 2 trials in 2016 for the treatment of diabetic macular edema (DME).
KalVista is also rapidly advancing orally delivered inhibitors through pre-clinical testing. These drugs will not only expand the therapeutic options for DME patients but also enable KalVista to expand its disease portfolio into the treatment of HAE and other kallikrein-related disorders. In addition, KalVista continues to expand its small molecule portfolio towards additional therapeutic targets to fully exploit its research expertise with serine proteases for the treatment of unmet clinical needs.
Others: * On July 22, 2015, KalVista Pharmaceuticals, a research-led pharmaceutical company, announced it has raised $33 million in a Series B financing to support its research and clinical development programs. KalVista will use the funds to advance its proprietary portfolio of plasma kallikrein inhibitors for treating diabetic macular edema (DME) and hereditary angioedema (HAE). Alongside the existing investors, Novo A/S and SV Life Sciences, the round included additional international healthcare investors experienced in plasma kallikrein targeted mechanisms led by RA Capital Management and including Longwood Fund and Venrock.
Therapeutic area:
